A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN

Prior treatment

• IgAN secondary to another condition or other causes of mesangial IgA deposition including IgA vasculitis, evidence of nephrotic syndrome within 6 months of screening, or concomitant chronic renal disease in addition to IgAN
• Administration of live and live-attenuated vaccinations within 30 days prior to randomization

Other illness

• Active viral, bacterial or mycobacterial infections
• Known hypersensitivity to atacicept or any component of the formulated atacicept

Lab values

• Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months of screening)
• Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in the study

• Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments
• Diagnosis of IgAN as demonstrated by renal biopsy with total urine protein excretion ≥0.75 g per 24-hour or UPCR ≥0.75 mg/mg based on a 24-hour urine sample, and eGFR ≥30 ml/min/1.73m2
• On a stable prescribed SoC regimen according to local practice listed in Section 4 of the protocol
• Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at screening